{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:42:01Z","timestamp":1793072521410,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vaccine.2023.07.069","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T07:01:59Z","timestamp":1699599719000},"page":"S9-S24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"S1","title":["Vaccine value profile for Chikungunya"],"prefix":"10.1016","volume":"42","author":[{"given":"Ximena","family":"Flandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clairissa A.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Palani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaja","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cate","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Perea","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Hutubessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanat","family":"Khazhidinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Lambach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Maure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana P.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Rosewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushant","family":"Sahastrabuddhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Tufet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Wilder-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.C.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Bourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.T.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.07.069_b0005","doi-asserted-by":"crossref","DOI":"10.1289\/EHP5899","article-title":"Current and Projected Distributions of Aedes aegypt and Ae. albopictus in Canada and the U.S","volume":"128","author":"Khan","year":"2020","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.vaccine.2023.07.069_b0010","unstructured":"Mosquito maps n.d. https:\/\/www.ecdc.europa.eu\/en\/disease-vectors\/surveillance-and-disease-data\/mosquito-maps (accessed July 5, 2023)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0015","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1016\/j.vaccine.2018.10.033","article-title":"Defining a correlate of protection for chikungunya virus vaccines","volume":"37","author":"Milligan","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.069_b0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0255-0857(21)01984-8","article-title":"Chikungunya fever: A re-emerging viral infection","volume":"26","author":"Chhabra","year":"2008","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.vaccine.2023.07.069_b0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.antiviral.2013.06.009","article-title":"Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy","volume":"99","author":"Thiberville","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2023.07.069_b0030","doi-asserted-by":"crossref","first-page":"e0009055","DOI":"10.1371\/journal.pntd.0009055","article-title":"Measuring the global burden of chikungunya and Zika viruses: A systematic review","volume":"15","author":"Puntasecca","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tmaid.2017.01.004","article-title":"Long-term sequelae of chikungunya virus disease: A systematic review","volume":"15","author":"van Aalst","year":"2017","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b9000","doi-asserted-by":"crossref","first-page":"636","DOI":"10.15585\/mmwr.mm7223a5","article-title":"Notes from the Field: Chikungunya Outbreak \u2014 Paraguay, 2022\u20132023","volume":"72","author":"Torales","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.07.069_b0040","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1017\/S0950268818000341","article-title":"Individual and contextual risk factors for chikungunya virus infection: the SEROCHIK cross-sectional population-based study","volume":"146","author":"Fred","year":"2018","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2023.07.069_b0045","unstructured":"Centers for Disease Control and Prevention, Brunette GW, editors. CDC yellow book 2020: health information for international travel. New York, NY: Oxford University Press; 2019."},{"key":"10.1016\/j.vaccine.2023.07.069_b0050","unstructured":"Ageing and health 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health (accessed May 4, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.actatropica.2018.09.003","article-title":"A scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control","volume":"188","author":"Silva","year":"2018","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2023.07.069_b0060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2015.04.016","article-title":"Chikungunya: Evolutionary history and recent epidemic spread","volume":"120","author":"Weaver","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2023.07.069_b0065","unstructured":"Chikungunya fact sheet 2022. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/chikungunya (accessed April 30, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0070","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(11)60281-X","article-title":"Chikungunya: a re-emerging virus","volume":"379","author":"Burt","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.07.069_b0075","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.1128\/JVI.00370-14","article-title":"High Level of Vector Competence of Aedes aegypti and Aedes albopictus from Ten American Countries as a Crucial Factor in the Spread of Chikungunya Virus","volume":"88","author":"Vega-R\u00faa","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.07.069_b0080","doi-asserted-by":"crossref","first-page":"e08347","DOI":"10.7554\/eLife.08347","article-title":"The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus","volume":"4","author":"Kraemer","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.vaccine.2023.07.069_b0085","unstructured":"Symptoms, Diagnosis, & Treatment | Chikungunya virus | CDC 2022. https:\/\/www.cdc.gov\/chikungunya\/symptoms\/index.html (accessed May 3, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0090","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.3201\/eid2412.170639","article-title":"Excess Mortality and Causes Associated with Chikungunya, Puerto Rico, 2014\u20132015","volume":"24","author":"Freitas","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0095","doi-asserted-by":"crossref","first-page":"e0006510","DOI":"10.1371\/journal.pntd.0006510","article-title":"Mother-to-child transmission of Chikungunya virus: A systematic review and meta-analysis","volume":"12","author":"Contopoulos-Ioannidis","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0100","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMra1406035","article-title":"Chikungunya Virus and the Global Spread of a Mosquito-Borne Disease","volume":"372","author":"Weaver","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.069_b0105","doi-asserted-by":"crossref","first-page":"390","DOI":"10.12688\/f1000research.11078.2","article-title":"Cardiovascular involvement and manifestations of systemic Chikungunya virus infection: A systematic review","volume":"6","author":"Alvarez","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.vaccine.2023.07.069_b0110","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1186\/ar4137","article-title":"Predictors of Chikungunya rheumatism: a prognostic survey ancillary to the TELECHIK cohort study","volume":"15","author":"G\u00e9rardin","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.vaccine.2023.07.069_b0115","doi-asserted-by":"crossref","unstructured":"Ferreira FCP de ADM, da Silva ASV, Recht J, Guaraldo L, Moreira MEL, de Siqueira AM, et al. Vertical transmission of chikungunya virus: A systematic review. PLoS One 2021; 16: e0249166. https:\/\/doi.org\/10.1371\/journal.pone.0249166.","DOI":"10.1371\/journal.pone.0249166"},{"key":"10.1016\/j.vaccine.2023.07.069_b0120","doi-asserted-by":"crossref","first-page":"e0010069","DOI":"10.1371\/journal.pntd.0010069","article-title":"The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines","volume":"16","author":"Bettis","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0125","doi-asserted-by":"crossref","first-page":"S441","DOI":"10.1093\/infdis\/jiw390","article-title":"Epidemiology of Chikungunya in the Americas","volume":"214","author":"Yactayo","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0130","article-title":"Circulation of Chikungunya virus East-Central-South African genotype during the 2020\u201321 outbreak in S\u00e3o Paulo State","volume":"2","author":"Maeda","year":"2022","journal-title":"Brazil J Clin Virol Plus"},{"key":"10.1016\/j.vaccine.2023.07.069_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.689979","article-title":"Molecular Epidemiology, Evolution and Reemergence of Chikungunya Virus in South Asia","volume":"12","author":"Sharif","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2023.07.069_b0140","unstructured":"Information for travellers to areas with chikungunya transmission. European Centre for Disease Prevention and Control 2022. https:\/\/www.ecdc.europa.eu\/en\/chikungunya\/threats-and-outbreaks\/information-travellers (accessed May 4, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pt.2014.12.008","article-title":"Chikungunya on the move","volume":"31","author":"Johansson","year":"2015","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2023.07.069_b0150","doi-asserted-by":"crossref","first-page":"ofx234","DOI":"10.1093\/ofid\/ofx234","article-title":"The Identification of Risk Factors for Chronic Chikungunya Arthralgia in Grenada, West Indies: A Cross-Sectional Cohort Study","volume":"5","author":"Heath","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0155","doi-asserted-by":"crossref","first-page":"671","DOI":"10.5811\/westjem.2016.9.30904","article-title":"Dengue, Zika and Chikungunya: Emerging Arboviruses in the New World","volume":"17","author":"Patterson","year":"2016","journal-title":"WestJEM"},{"key":"10.1016\/j.vaccine.2023.07.069_b0160","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1186\/s12889-018-6172-4","article-title":"Socioeconomic and demographic predictors of resident knowledge, attitude, and practice regarding arthropod-borne viruses in Panama","volume":"18","author":"Whiteman","year":"2018","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2023.07.069_b0165","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1007\/s00253-020-10437-x","article-title":"Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection","volume":"104","author":"Kumar","year":"2020","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2023.07.069_b0170","doi-asserted-by":"crossref","first-page":"e0005637","DOI":"10.1371\/journal.pntd.0005637","article-title":"Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques","volume":"11","author":"Broeckel","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0175","doi-asserted-by":"crossref","first-page":"8213","DOI":"10.1128\/JVI.01032-14","article-title":"Chikungunya Viruses That Escape Monoclonal Antibody Therapy Are Clinically Attenuated, Stable, and Not Purified in Mosquitoes","volume":"88","author":"Pal","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.07.069_b0180","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fcimb.2018.00345","article-title":"Cellular and Molecular Immune Response to Chikungunya Virus Infection","volume":"8","author":"Tanabe","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2023.07.069_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41426-017-0010-0","article-title":"Broad and long-lasting immune protection against various Chikungunya genotypes demonstrated by participants in a cross-sectional study in a Cambodian rural community","volume":"7","author":"Auerswald","year":"2018","journal-title":"Emerging Microbes Infect"},{"key":"10.1016\/j.vaccine.2023.07.069_b0190","doi-asserted-by":"crossref","first-page":"e0009259","DOI":"10.1371\/journal.pntd.0009259","article-title":"Climatic and socio-economic factors supporting the co-circulation of dengue, Zika and chikungunya in three different ecosystems in Colombia","volume":"15","author":"Morgan","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0195","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI84417","article-title":"Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies","volume":"127","author":"Silva","year":"2017","journal-title":"J Clin Investig"},{"key":"10.1016\/j.vaccine.2023.07.069_b0200","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01622-18","article-title":"Epidemiological evidence for lineage-specific differences in the risk of Inapparent Chikungunya virus infection","volume":"93","author":"Bustos Carrillo","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.07.069_b0205","first-page":"2","article-title":"Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus","author":"Roques","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2023.07.069_b0210","doi-asserted-by":"crossref","first-page":"e0007047","DOI":"10.1371\/journal.pntd.0007047","article-title":"Dengue and chikungunya among outpatients with acute undifferentiated fever in Kinshasa, Democratic Republic of Congo: A cross-sectional study","volume":"13","author":"Proesmans","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0215","article-title":"Understanding the evolution and spread of chikungunya virus in the Americas using complete genome sequences","volume":"3","author":"Sahadeo","year":"2017","journal-title":"Virus Evolut"},{"key":"10.1016\/j.vaccine.2023.07.069_b0220","unstructured":"Chikungunya \u2013 Congo 2022. https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/01-may-2019-chikungunya-congo-en (accessed May 5, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0225","doi-asserted-by":"crossref","first-page":"e0008159","DOI":"10.1371\/journal.pntd.0008159","article-title":"A comparative analysis of the 2007 and 2017 Italian chikungunya outbreaks and implication for public health response","volume":"14","author":"Caputo","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0230","unstructured":"Priority diseases. CEPI 2022. https:\/\/cepi.net\/research_dev\/priority-diseases\/ (accessed May 5, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0235","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.idcr.2016.07.008","article-title":"Neonatal encephalitis due to Chikungunya vertical transmission: First report in Brazil","volume":"5","author":"Bandeira","year":"2016","journal-title":"IDCases"},{"key":"10.1016\/j.vaccine.2023.07.069_b0240","doi-asserted-by":"crossref","unstructured":"Bandeira AC, Campos GS, Rocha VFD, Souza BS de F, Soares MBP, Oliveira AA, et al. Prolonged shedding of Chikungunya virus in semen and urine: A new perspective for diagnosis and implications for transmission. IDCases 2016; 6: 100\u20133. https:\/\/doi.org\/10.1016\/j.idcr.2016.10.007.","DOI":"10.1016\/j.idcr.2016.10.007"},{"key":"10.1016\/j.vaccine.2023.07.069_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2020.02.004","article-title":"Influence of herd immunity in the cyclical nature of arboviruses","volume":"40","author":"Ribeiro","year":"2020","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2023.07.069_b0250","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijid.2017.12.018","article-title":"Prevalence of chronic comorbidities in chikungunya: A systematic review and meta-analysis","volume":"67","author":"Badawi","year":"2018","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0255","unstructured":"Shepard DS. Cost and burden of dengue and chikungunya from the Americas to Asia; 2010."},{"key":"10.1016\/j.vaccine.2023.07.069_b0260","doi-asserted-by":"crossref","first-page":"e2137","DOI":"10.1371\/journal.pntd.0002137","article-title":"Chikungunya Virus-associated Long-term Arthralgia: A 36-month Prospective Longitudinal Study","volume":"7","author":"Schilte","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0265","unstructured":"Prevention | Chikungunya virus | CDC 2022. https:\/\/www.cdc.gov\/chikungunya\/prevention\/index.html (accessed May 5, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0270","unstructured":"Guidelines on Clinical Management of Chikungunya Fever 2022. https:\/\/www.who.int\/publications-detail-redirect\/guidelines-on-clinical-management-of-chikungunya-fever (accessed May 5, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0275","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3390\/v13071312","article-title":"Mother-to-Child Transmission of Arboviruses during Breastfeeding: From Epidemiology to Cellular Mechanisms","volume":"13","author":"Desgraupes","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.07.069_b0280","doi-asserted-by":"crossref","unstructured":"de St. Maurice A, Ervin E, Chu A. Ebola, Dengue, Chikungunya, and Zika Infections in Neonates and Infants. Clin Perinatol 2021; 48: 311\u201329. https:\/\/doi.org\/10.1016\/j.clp.2021.03.006.","DOI":"10.1016\/j.clp.2021.03.006"},{"key":"10.1016\/j.vaccine.2023.07.069_b0285","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.vaccine.2016.03.076","article-title":"Status of research and development of vaccines for chikungunya","volume":"34","author":"Smalley","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.069_b0290","unstructured":"Merriam S, Behrendt H. Increasing vaccine uptake in lowand middle-income countries; 2020."},{"key":"10.1016\/j.vaccine.2023.07.069_b0295","unstructured":"UNICEF, WHO, IFRC and MSF announce the establishment of a global Ebola vaccine stockpile 2022. https:\/\/www.who.int\/news\/item\/12-01-2021-unicef-who-ifrc-and-msf-announce-the-establishment-of-a-global-ebola-vaccine-stockpile (accessed May 5, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0300","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4269\/ajtmh.17-0668","article-title":"Chikungunya Virus Disease among Travelers\u2014United States, 2014\u20132016","volume":"98","author":"Lindsey","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2023.07.069_b0305","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taad008","article-title":"Chikungunya: risks for travellers","volume":"30","author":"Simon","year":"2023","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2023.07.069_b0310","doi-asserted-by":"crossref","first-page":"e0007327","DOI":"10.1371\/journal.pntd.0007327","article-title":"Prevalence of chronic chikungunya and associated risks factors in the French West Indies (La Martinique): A prospective cohort study","volume":"14","author":"Bertolotti","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0315","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41584-019-0276-9","article-title":"Rheumatic manifestations of chikungunya: emerging concepts and interventions","volume":"15","author":"Suhrbier","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.vaccine.2023.07.069_b0320","unstructured":"Chikungunya - PAHO\/WHO | Pan American Health Organization 2022. https:\/\/www.paho.org\/en\/topics\/chikungunya (accessed May 6, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b9005","unstructured":"Vijay Shankar Balakrishnan, WHO launches global initiative for arboviral diseases, 2016, https:\/\/www.thelancet.com\/journals\/lanmic\/article\/PIIS2666-5247(22)00130-6\/fulltext."},{"key":"10.1016\/j.vaccine.2023.07.069_b9010","unstructured":"Launch of the WHO Global Arbovirus Initiative, Meeting report 31 March 2022, https:\/\/cdn.who.int\/media\/docs\/default-source\/world-health-data-platform\/technical-advisory-groups\/arbovirus\/glai-launch-meeting-summary_webinar_31-march-2022.pdf."},{"key":"10.1016\/j.vaccine.2023.07.069_b0325","unstructured":"About our Alliance 2022. https:\/\/www.gavi.org\/our-alliance\/about (accessed May 6, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0330","unstructured":"Vaccine investment strategy 2022. https:\/\/www.gavi.org\/our-alliance\/strategy\/vaccine-investment-strategy (accessed May 6, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0335","unstructured":"Valneva Announces Initiation of Adolescent Phase 3 Trial for its Single-Shot Chikungunya Vaccine Candidate. Valneva SE; 2022."},{"key":"10.1016\/j.vaccine.2023.07.069_b0340","unstructured":"Our portfolio. CEPI 2022. https:\/\/cepi.net\/research_dev\/our-portfolio\/ (accessed May 6, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0345","unstructured":"IVI and BBIL launch global Chikungunya vaccine Phase II\/III trial in Costa Rica. IVI 2021. https:\/\/www.ivi.int\/ivi-and-bbil-launch-global-chikungunya-vaccine-phase-ii-iii-trial-in-costa-rica\/ (accessed May 6, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0350","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1016\/S2214-109X(18)30346-2","article-title":"Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study","volume":"6","author":"Gouglas","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.07.069_b0355","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3389\/fimmu.2020.00592","article-title":"Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections","volume":"11","author":"Schrauf","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.07.069_b0360","unstructured":"Guidelines for the Clinical Diagnosis and Treatment of Dengue, Chikungunya, and Zika. Washington, D.C.: Pan American Health Organization; 2022."},{"key":"10.1016\/j.vaccine.2023.07.069_b0365","article-title":"The global emergence of Chikungunya infection: An integrated view","author":"Manzoor","year":"2021","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2023.07.069_b0370","unstructured":"Diagnostic Testing | Chikungunya virus | CDC 2022. https:\/\/www.cdc.gov\/chikungunya\/hc\/diagnostic.html (accessed May 6, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0375","doi-asserted-by":"crossref","first-page":"e4261","DOI":"10.1371\/journal.pone.0004261","article-title":"IL-1\u03b2, IL-6, and RANTES as Biomarkers of Chikungunya Severity","volume":"4","author":"Ng","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.07.069_b0380","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/infdis\/jiq042","article-title":"Persistent Arthralgia Induced by Chikungunya Virus Infection is Associated with Interleukin-6 and Granulocyte Macrophage Colony-Stimulating Factor","volume":"203","author":"Chow","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0385","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106225","article-title":"Innovative trial designs and analyses for vaccine clinical development","volume":"100","author":"Liu","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.vaccine.2023.07.069_b0395","unstructured":"Agnihothram S. Approaches to Assessing Effectiveness of Chikungunya Vaccines 2019."},{"key":"10.1016\/j.vaccine.2023.07.069_b0400","unstructured":"Merck admits defeat in chikungunya vaccine race with Valneva n.d. https:\/\/www.fiercebiotech.com\/deals\/merck-admits-defeat-race-valneva-get-first-chikungunya-vaccine-market (accessed July 5, 2023)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0405","unstructured":"Emergent sells a trio of vaccines to Bavarian Nordic for $270M+ n.d. https:\/\/www.fiercepharma.com\/manufacturing\/after-jynneos-success-bavarian-nordic-hands-over-380m-emergents-typhoid-and-cholera (accessed July 5, 2023)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0410","unstructured":"Valneva to Present its Chikungunya Vaccine Candidate at the ASTMH 2021 Annual Meeting. Saint-Herblain (France): Valneva SE; 2021."},{"key":"10.1016\/j.vaccine.2023.07.069_b0415","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.2147\/DDDT.S181574","article-title":"Recent development in the strategies projected for chikungunya vaccine in humans","volume":"12","author":"Goyal","year":"2018","journal-title":"DDDT"},{"key":"10.1016\/j.vaccine.2023.07.069_b0420","unstructured":"Valneva Austria GmbH. A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study To Evaluate Safety And Immunogenicity Of A Live-Attenuated Chikungunya Virus Vaccine Candidate In Adults Aged 18 Years And Above. clinicaltrials.gov; 2021."},{"key":"10.1016\/j.vaccine.2023.07.069_b0425","unstructured":"Butantan Institute. A Multicenter, Randomized, Controlled, Double Blinded Pivotal Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Adolescents Aged 12 Years to <18 Years. clinicaltrials.gov; 2022."},{"key":"10.1016\/j.vaccine.2023.07.069_b0430","unstructured":"Emergent BioSolutions. A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted). clinicaltrials.gov; 2021."},{"key":"10.1016\/j.vaccine.2023.07.069_b0435","unstructured":"Emergent BioSolutions. A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents. clinicaltrials.gov; 2022."},{"key":"10.1016\/j.vaccine.2023.07.069_b0440","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults. clinicaltrials.gov; 2020."},{"key":"10.1016\/j.vaccine.2023.07.069_b0445","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jama.2020.2477","article-title":"Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial","volume":"323","author":"Chen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.07.069_b0450","unstructured":"Themis Bioscience GmbH. Double Blinded, Randomized, Priorix\u00ae- and Placebo-controlled, Trial to Evaluate the Optimal Dose of MV-CHIK Vaccine (Against Chikungunya Virus) in Regard to Immunogenicity, Safety and Tolerability in Healthy Volunteers. clinicaltrials.gov; 2021."},{"key":"10.1016\/j.vaccine.2023.07.069_b0455","unstructured":"Themis Bioscience GmbH. Observer Blinded, Randomised Study to Investigate Safety, Tolerability and Long-term Immunogenicity of Different Dose Regimens and Formulations of MV-CHIK in Healthy Volunteers. clinicaltrials.gov; 2021."},{"key":"10.1016\/j.vaccine.2023.07.069_b0460","unstructured":"Themis Bioscience GmbH. Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area. clinicaltrials.gov; 2021."},{"key":"10.1016\/j.vaccine.2023.07.069_b0465","unstructured":"Vaccines and Related Biological Products Advisory Committee Meeting: MV-CHIK. Vienna, Austria: Themis Bioscience GmbH; 2019."},{"key":"10.1016\/j.vaccine.2023.07.069_b0470","unstructured":"International Vaccine Institute. A Phase II\/III Adaptive Seamless Design, Randomized, Controlled Trial To Evaluate Safety And Immunogenicity of 2 Dose-Regimen Of BBV87 Chikungunya Vaccine In Healthy Subjects Aged 12 to 65 Years In Panama, Colombia, and Thailand. clinicaltrials.gov; 2022."},{"key":"10.1016\/j.vaccine.2023.07.069_b0475","unstructured":"CTRI. A Phase II\/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age. Clinical Trials Registry - India 2022. http:\/\/ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=56796&EncHid=&userName=CTRI\/2021\/09\/036179 (accessed May 6, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0480","unstructured":"University of Oxford. A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Chikungunya Virus (CHIKV) Vaccine ChAdOx1 Chik in Healthy Adult Volunteers. clinicaltrials.gov; 2019."},{"key":"10.1016\/j.vaccine.2023.07.069_b0485","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1038\/s41467-021-24906-y","article-title":"A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial","volume":"12","author":"Folegatti","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.07.069_b0490","unstructured":"University of Oxford. A Single Centre, Double-blind, Double-dummy Placebo-controlled, Randomised Phase Ib Study to Evaluate the Safety & Immunogenicity of the Candidate Chikungunya Vaccine ChAdOx1 Chik & the Zika Vaccine ChAdOx1 Zika in Healthy Adults in Mexico. clinicaltrials.gov; 2022."},{"key":"10.1016\/j.vaccine.2023.07.069_b0495","unstructured":"ModernaTX, Inc. A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of VAL-181388 in Healthy Adults in a Non Endemic Chikungunya Region. clinicaltrials.gov; 2020."},{"key":"10.1016\/j.vaccine.2023.07.069_b0500","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijid.2018.11.058","article-title":"Safety and immunogenicity of a mRNA-based chikungunya vaccine in a phase 1 dose-ranging trial","volume":"79","author":"Shaw","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.069_b0505","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1186\/s12889-021-12040-9","article-title":"How can the public health impact of vaccination be estimated?","volume":"21","author":"Echeverria-Londono","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2023.07.069_b0510","unstructured":"Bloch D. The Cost And Burden Of Chikungunya In The Americas. Public Health Theses. Yale University, 2016."},{"key":"10.1016\/j.vaccine.2023.07.069_b0515","unstructured":"Hatchett R. The world needs a Chikungunya vaccine. CEPI 2019. https:\/\/cepi.net\/news_cepi\/the-world-needs-a-chikungunya-vaccine\/ (accessed May 6, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0520","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1038\/s41598-017-03566-3","article-title":"Modelling the effects of global climate change on Chikungunya transmission in the 21st century","volume":"7","author":"Tjaden","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.07.069_b0525","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.3841999","article-title":"The Full Value of Vaccine Assessments (FVVA): A Framework to Assess and Communicate the Value of Vaccines for Investment and Introduction Decision Making","author":"Hutubessy","year":"2021","journal-title":"SSRN J"},{"key":"10.1016\/j.vaccine.2023.07.069_b0530","unstructured":"Vector Control Advisory Group (VCAG) n.d. https:\/\/www.who.int\/groups\/vector-control-advisory-group (accessed July 5, 2023)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0535","unstructured":"Technical Advisory Group on Arbovirus n.d. https:\/\/www.who.int\/groups\/technical-advisory-group-on-arbovirus (accessed July 5, 2023)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0540","unstructured":"World Health Organization. WHO Evidence Considerations for Vaccine Policy Development (ECVP) n.d. https:\/\/www.who.int\/publications\/m\/item\/who-evidence-considerations-for-vaccine-policy-development-(ecvp) (accessed June 10, 2022)."},{"key":"10.1016\/j.vaccine.2023.07.069_b0545","doi-asserted-by":"crossref","unstructured":"Malarski M, Hasso-Agopsowicz M, Soble A, Mok W, Mathewson S, Vekemans J. Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance\u2019s 2018 Vaccine Investment Strategy: report from an expert survey. F1000Res 2019; 8: 1685. https:\/\/doi.org\/10.12688\/f1000research.20100.1.","DOI":"10.12688\/f1000research.20100.1"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23009155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23009155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T10:10:02Z","timestamp":1728987002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23009155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":112,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0264410X23009155"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.069","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine value profile for Chikungunya","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}